Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Yury N. Lazutin"'
Autor:
Oleg I. Kit, Alla I. Shikhlyarova, Yury N. Lazutin, Tamara G. Airapetova, Igor A. Leiman, Anna V. Chubaryan, Igor N. Turkin, Sergey P. Pyltsin
Publikováno v:
Cardiometry.
Autor:
Pavel A. Anistratov, Inna Arnoldovna Novikova, Anna V. Chubaryan, Elena S. Bondarenko, Oleg I. Kit, Evgeniya M. Nepomnyashchaya, Yury N. Lazutin, Sergey P. Pyltsin, Tamara G. Ayrapetova, Rukiyat Isaeva, Elena P. Ulianova
Publikováno v:
Journal of Clinical Oncology. 34:e20071-e20071
e20071Background: The purpose of the study was to assess the rate of ALK-positive NSCLC patients in dependence on their age, gender, smoking status and localization of metastases. Methods: ALK expr...
Autor:
Oleg I. Kit, Anna V. Chubaryan, Liubov Yu Vladimirova, Anna Pavlovna Kharitonova, Tamara G. Ayrapetova, Igor A. Leyman, Yury N. Lazutin, Gennadiy Z. Sergostyants, Pavel A. Anistratov, Sergey P. Pyltsin
Publikováno v:
Journal of Clinical Oncology. 34:e20072-e20072
e20072Background: Metformin is a drug prescribed for the treatment of type II diabetes, a widespread disease worldwide. Ability of metformin to inhibit the growth of malignant tumors in tissue cult...
Autor:
Yury N. Lazutin, Igor A. Leyman, Gennadiy Z. Sergostyants, Anna Pavlovna Kharitonova, Galina I. Zakora, Sergey P. Pyltsin, Elena S. Bondarenko, Liubov Yu Vladimirova, Rukiyat Isaeva, Anna V. Chubaryan, Elena Yurievna Zlatnik, Igor N. Turkin, Oleg I. Kit, Tamara G. Ayrapetova, Inna Arnoldovna Novikova, Pavel A. Anistratov, Olesya N. Selyutina
Publikováno v:
Journal of Clinical Oncology. 34:e20058-e20058
e20058Background: In recent years, new methods of induction CIT with recombinant cytokines have developed. Refnot drug in iCIT demonstrated improvement of the overall response rate to the treatment...
Autor:
Yury N. Lazutin, Sergey P. Pyltsin, Pavel A. Anistratov, Aleksey Yurievich Maksimov, Elena P. Ulianova, Evgeniya M. Nepomnyashchaya, Inna Arnoldovna Novikova
Publikováno v:
Journal of Clinical Oncology. 33:e18536-e18536
e18536 Background: The purpose of the study was to analyze the effectiveness of immunohistochemistry (IHC) in detecting ALK in tissues of NSCLC. Methods: 50 patients with NSCLC living in the South ...
Autor:
Yury N. Lazutin, Sergei A. Zinkovich, Liubov Yu Vladimirova, Anna Pavlovna Kharitonova, Sergey P. Pyltsin
Publikováno v:
Journal of Clinical Oncology. 33:e18523-e18523
e18523 Background: In contrast to adjuvant chemotherapy (CT), neoadjuvant CT (NCT) is not currently a standard treatment for NSCLC, and further clinical trials are required to prove its benefits. H...
Autor:
Liubov Yu Vladimirova, Igor A. Leyman, Dmitry I. Vodolazhsky, Konstantin Vladimirovich Dvadnenko, Denis D. Olejnikov, Elena N. Gudueva, Yury N. Lazutin, Yaroslav S. Enin
Publikováno v:
Journal of Clinical Oncology. 33:e18534-e18534
e18534 Background: EGFR gene mutations are an effective marker for targeted therapy of lung cancer. EGFR plays an important role in proliferation of epithelial cells. EGFR overexpression is detecte...
Autor:
Pavel A. Anistratov, Anna P. Charitonova, Igor A. Leyman, Yury N. Lazutin, Sergey P. Pyltsin, Gennadiy Z. Sergostyants, Liubov Yu Vladimirova
Publikováno v:
Journal of Clinical Oncology. 32:e18530-e18530
e18530 Background: In recent years, much attention is paid to the study of morphological predictors of prognosis of lung cancer in order to personalize therapy. In this paper the comparative immuno...
Autor:
Gennadiy Z. Sergostyants, Yury N. Lazutin, Igor A. Leyman, Sergey P. Pyltsin, Liubov Yu Vladimirova, Pavel A. Anistratov, Anna P. Charitonova
Publikováno v:
Journal of Clinical Oncology. 32:e18532-e18532
e18532 Background: Neoangiogenesis in the tumor tissue is an important factor of growth and metastasis of malignant neoplasms. Tumor vascular invasion is a prognostic factor for patients with NSCLC...
Autor:
Gennadiy Z. Sergostyants, Yury N. Lazutin, Pavel A. Anistratov, Sergey P. Pyltsin, Anna P. Charitonova, Igor A. Leyman, Liubov Yu Vladimirova
Publikováno v:
Journal of Clinical Oncology. 32:e18531-e18531
e18531 Background: Chemotherapy is the standard adjuvant treatment of lung cancer, but it's somewhat ineffective and controversial at the 1 stage of the disease. The authors have developed an origi...